Heartflow, Inc.’s Lock-Up Period Will Expire on February 4th (NASDAQ:HTFL)

Heartflow’s (NASDAQ:HTFL) lock-up period is set to end on Wednesday, February 4th. Heartflow had issued 16,666,667 shares in its public offering on August 8th. The total size of the offering was $316,666,673 based on an initial share price of $19.00. After the end of Heartflow’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Stifel Nicolaus raised their price target on shares of Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Canaccord Genuity Group boosted their price objective on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, JPMorgan Chase & Co. raised their target price on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Heartflow has a consensus rating of “Hold” and a consensus price target of $38.60.

Heartflow Stock Performance

Shares of HTFL stock opened at $31.21 on Wednesday. The business’s fifty day moving average is $30.59. The firm has a market cap of $2.66 billion and a price-to-earnings ratio of -17.24. Heartflow has a 1-year low of $25.38 and a 1-year high of $41.22.

Insiders Place Their Bets

In other news, Director Jeffrey C. Lightcap acquired 40,000 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were purchased at an average price of $26.34 per share, for a total transaction of $1,053,600.00. Following the completion of the purchase, the director directly owned 40,000 shares of the company’s stock, valued at $1,053,600. This represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Hedge Funds Weigh In On Heartflow

A number of hedge funds have recently added to or reduced their stakes in the business. Perpetual Ltd acquired a new stake in shares of Heartflow during the fourth quarter worth $459,000. SG Americas Securities LLC bought a new stake in shares of Heartflow during the 4th quarter valued at about $312,000. JPMorgan Chase & Co. acquired a new stake in Heartflow during the third quarter worth about $13,887,000. Hudson Bay Capital Management LP bought a new position in Heartflow in the third quarter worth about $288,000. Finally, XXEC Inc. acquired a new position in Heartflow in the third quarter valued at approximately $1,004,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.